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Background: E-cadherin/CDH1 is one of the proteins involved in cell adhesion, and it is known that decreased
expression of E-cadherin induces lymph node metastasis in esophageal cancer. Beta catenin/CTNNB1, which is an
important component of the Wnt signaling pathway, binds to E-cadherin at the cell membrane, where the complex
of these two proteins functions in the stabilization of cell adhesion. However, its role in the pathogenesis of esophageal
cancer is still unknown.
Methods: This study included 86 patients with esophageal cancer who underwent surgery between 1998 and 2007.
The expression of the E-cadherin/CDH1 gene product (E-cadherin/CDH1) and that of the beta catenin/CTNNB1 protein in
the cell membrane were analyzed by immunohistochemistry. We examined the correlations among CDH1 or CTNNB1
expression, clinicopathological factors, and the prognosis of patients with ESCC.
Results: CDH1 and CTNNB1 were expressed in 52.3 % (45/86) and 36.0 % (31/86) of tumor samples, respectively. Both
CDH1 and CTNNB1 were co-expressed in 22.1 % (19/86) of esophageal cancer tissues. CDH1 expression correlated with
the p-stage (stages I–II vs stages III–IV, p = 0.032), T factor (T1–2 vs T3–4, p = 0.0088), and lymphatic invasion (p = 0.019).
However, CDH1 expression did not correlate with the N factor or the blood vessel invasion. CTNNB1 expression
correlated with the T factor (T1–2 vs T3–4, p = 0.0015), p-stage (stages I–II vs stages III–IV, p = 0.030), and lymphatic
invasion (p = 0.007). The CDH1(+)/CTNNB1(+) phenotype was inversely correlated with the T factor, N factor, p-stage,
lymphatic invasion, and blood vessel invasion. Furthermore, patients whose tumors were double-positive for CDH1 and
CTNNB1 had a significantly higher survival rate than those whose tumors were negative for CDH1 or CTNNB1 (log-rank
test, p = 0.0192). The T factor and N factor had a strong negative correlation with double-positive tumors. These were
both independent prognostic factors, as was the double-positive phenotype. A univariate analysis indicated that the T
factor, the N factor, and CDH1 and CTNNB1 co-expression were significant variables that predicted survival (hazard ratio,
2.387; 95 % confidence interval, 1.115–5.102; p = 0.025).
Conclusions: Decreased expression of CDH1 or CTNNB1 in the cell membranes of cancer cells is associated with poor
survival of patients with esophageal cancer.
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The prognosis of patients with esophageal cancer remains
poor, which highlights the need for the development of
new treatment strategies. Today, the overall 5-year sur-
vival rate is less than 50 % despite the use of multimodal
therapies. To develop novel treatment strategies, it is
important to understand the biological behavior of
esophageal cancer. Recent studies have found that several
genes and molecules are involved in the origin and/or pro-
gression of esophageal cancer, including TP53 [1], deleted
in esophageal cancer 1 (DEC1) [2], deleted in colorectal
cancer (DCC) [3], deleted in lung cancer 1 (DLC1) [4],
cyclinD1 [5], and adenomatous polyposis coli (APC) [6].
However, the precise mechanisms that underlie the devel-
opment and progression of esophageal squamous cell
carcinoma (ESCC) are still unclear.
The E-cadherin/CDH1 gene product is a trans-
membrane protein that is involved in cell adhesion in
normal epithelia [7–9]. E-cadherin is also involved in the
stabilization of cell adhesion in normal cells and in sig-
nal transduction through connections with beta catenin
[10]. Beta catenin/CTNNB1, which is a major compo-
nent of the Wnt signaling pathway, plays an important
role in the carcinogenesis of various malignancies. Beta
catenin also functions in cell-to-cell adhesion [11–14].
Decreased expression of CDH1 is associated with the
poor prognosis of patients with esophageal cancer [15, 16].
However, the involvement of decreased expression of
CTNNB1 at the cell membrane is unclear in metastasis,
and the progression of esophageal cancer is unclear.
In this paper, we investigated the clinicopathological
significance of CDH1 and CTNNB1 protein expression
in the cell membrane and the relation between the co-




Samples were obtained from 86 patients with ESCC who
underwent surgery at the Department of Gastroentero-
logical Surgery, Nagoya City University Medical School
between 1997 and 2005. None of the patients received
pre-operative chemotherapy or radiation. The tumors
were classified according to the sixth UICC guidelines
for clinical and pathological studies on carcinoma of the
esophagus. R0/R1 resection was performed on all pa-
tients. T4 cases included combined resection of 6
pleuras, 3 pericardia, 11 thoracic ducts, and 4 tracheas
because of the invasion of the structure. Stage IV cases
included 20 M1a (cervical lymph node metastasis of Ut
cases and celiac lymph node metastasis of Lt) and
14M1b (10 non-regional lymph node metastases of Mt
cases and 4 lung metastases). We performed combined
resection of the partial lung in lung metastasis cases.Immunohistochemistry
Immunohistochemical staining was performed on
formalin-fixed, paraffin-embedded primary human ESCC
tissues using monoclonal anti-E-cadherin (Dako, CA,
USA) or anti-beta catenin antibodies (BD Biosciences,
Lexington, KY, USA) at dilutions of 1:50 and 1:500,
respectively. Paraffin-embedded sections of tumors were
deparaffinized, rehydrated, heat-treated by microwaving
in 10 mM citrate buffer for 15 min for antigen retrieval,
and cooled to room temperature. The sections were then
treated with 0.3 % H2O2 in methanol for 30 min to
neutralize endogenous peroxidase activity, after which
the sections were blocked with normal goat serum for
10 min. Next, the slides were incubated with antibody
H-100 overnight at room temperature in a humidified
chamber. Immunoreactive proteins were detected by a
DAKO Envision System using HRP and DAB, which was
followed by a hematoxylin counterstain. Immunostaining
for E-cadherin/CDH1 and beta catenin/CTNNB1 was
subjectively assessed by two independent investigators
(HI and TT), and discordant results were resolved by
consultation with a third investigator (TW). In regard to
the evaluation of CDH1 expression, immunostaining
was considered positive only when unequivocally strong
staining of the cell membrane was present in more than
50 % of the tumor cells, as analyzed by light microscopy.
Cases with only faint staining were regarded as negative.
For the evaluation of CTNNB1 expression, immuno-
staining was scored as positive only when unequivocally
strong staining of the cell membrane was present in
more than 50 % of the tumor cells similar to CDH1.
Cases with only faint staining were regarded as negative.
Statistical analysis
The chi-squared test was used to compare the correla-
tions between clinicopathological factors and the expres-
sion of CDH1 and CTNNB1. The cumulative survival
rates were calculated according to the Kaplan-Meier
method and were compared by the Cox-Mantel test. A
multivariate analysis by the Cox proportional hazard risk
model was used to obtain the conditional risk of death
due to ESCC. Differences were considered statistically
significant when p values were less than 0.05.
Results
The correlation of clinicopathological factors with the
expression of CDH1 and CTNNB1
First, we investigated the expression of the CDH1 and
CTNNB1 proteins in ESCC tissues by immunohistochem-
istry. Representative images of cancer tissues immuno-
stained for CDH1 and CTNNB1 are shown in Fig. 1a, b
and in Fig. 2a, b, respectively. In normal tissue, both
CDH1 and CTNNB1 are strongly expressed. Typical posi-





















Fig. 1 Representative immunostains for CDH1 (×100). a Negative CDH1 staining in the cell membrane of tumor cells. b Positive CDH1 staining in
the cell membrane of tumor cells. c Expression of CDH1 in normal esophageal mucosa. d Kaplan-Meier survival curve for patients with esophageal
cancer whose tumors were classified as either positive or negative for CDH1 expression by IHC. CDH1 status did not demonstrate a significant
(log-rank, p = 0.1289) relation with patient survival
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CTNNB1 was positive in 52.3 % (45/86) and 36.0 % (31/86)
of patients, respectively (Table 1). CDH1 expression
correlated with the p-stage (stages I–II vs stages III–IV,
p = 0.032), T factor (T1–2 vs T3–4, p = 0.0088), and
lymphatic invasion (p = 0.019). However, it did not correl-
ate with the N factor or the v factor. CTNNB1 expression
correlated with the p-stage (stages I–II vs stages III–IV,
p = 0.030) and Ly factor (p = 0.007) (Table 1). Both CDH1
and CTNNB1 were co-expressed in 22.1 % (19/86) of
esophageal cancer tissues. The CDH1(+)/CTNNB1(+)
phenotype was inversely correlated with the T factor,
N factor, p-stage, lymphatic invasion, and blood vessel
invasion (Table 2). Additionally, no correlations were
observed between the expression of CDH1 and that of
CTNNB1 (data not shown).
Survival curves and the expression of CDH1 and CTNNB1
Next, we investigated the correlation between positive
staining for CDH1 and CTNNB1 and the survival of
patients with ESCC after surgery. Neither CDH1 nor
CTNNB1 exerted a significant effect on patient survival
(Figs. 1d and 2d). Indeed, patients whose tumors were
positive for CDH1 by IHC did not demonstrate a signifi-
cantly longer survival after surgery than patients whose
tumors were negative (26.7 ± 2.29 months (n = 45) vs
20.9 ± 2.59 months (n = 41), respectively; p = 0.1289 byLog-rank test; Fig. 1d). Moreover, no significant dif-
ferences were observed with respect to survival after
surgery between patients whose tumors were positive
and patients whose tumors were negative for CTNNB1
(27.9 ± 2.97 months (n = 31) vs 21.5 ± 2.07 months (n = 55),
respectively; p = 0.1743 by Log-rank test; Fig. 2d).
However, the co-expression of CDH1 and CTNNB1
was associated with a significantly longer survival
after surgery compared with patients with negative
tumors (p = 0.0192) (Fig. 3).
A univariate analysis showed that, among the clinico-
pathological factors examined in this study, the extent of
the primary tumor (risk ratio, 6.289; p < 0.001), lymph
node metastasis (risk ratio, 5.812; p < 0.001), lymphatic
invasion (risk ratio, 5.917; p = 0.003), blood vessel inva-
sion (risk ratio, 3.135; p = 0.002), and positive im-
munostaining for CDH and CTNNB1 (risk ratio, 2.387;
p = 0.025) were statistically significant prognostic factors
(Table 3). A multivariate analysis revealed that CDH1
and CTNNB1 expression was not an independent prog-
nostic factor (data not shown).
Discussion
The loss of cellular adhesion results in increased inva-
siveness and metastatic ability of various types of cancer
cells. Reduced cellular adhesion has been linked to






















Fig. 2 Representative immunostains for CTNNB1 (×100). a Negative CTNNB1 staining in the cell membrane of tumor cells. b Positive CTNNB1
staining in the cell membrane of tumor cells. c Expression of CTNNB1 in normal esophageal mucosa. d Kaplan-Meier survival curve for patients
with esophageal cancer whose tumors were classified as either positive or negative for CTNNB1 by IHC. CTNNB1 status did not demonstrate a
significant (log-rank, p = 0.1743) relation with patient survival
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of cell polarity and intercellular adhesion. Additionally,
the CDH1 and CTNNB1 complex is involved in the
maintenance of cell-cell adhesion [10]. In normal cells,
the complex is localized to the cell membrane [17, 18].
Consistent with this finding, our current experiments
showed that both CDH1 and CTNNB1 were expressed in
the cell membrane in noncancerous cells (Figs. 1c and 2c).
Reduced expression of the cadherin-catenin complex in
various carcinomas has been reported, and the decreased
expression of these proteins has been found to be corre-
lated with high grade and advanced tumor stage, including
esophageal carcinoma [10, 19].
However, it is still unclear how CDH1 expression is
regulated in ESCC. Some factors such as hypermethyla-
tion [20], microRNA [21, 22], and PDX1 expression [23],
which have been shown to regulate the expression of
CDH1, should be investigated in future studies.
The cytoplasmic and nuclear expression of CTNNB1 is
controlled by Wnt-1, APC, and axis inhibitor 1/AXIN1
[24, 25]. Most of the mutations in APC result in a trun-
cated APC protein, which can form a complex with but
cannot degrade CTNNB1 [24, 26]. The CTNNB1 level in
the nucleus may also be increased by mutations in the
CTNNB1 gene itself, which may interfere with normal pro-
tein degradation [27, 28]. Thus, a number of mechanismsresult in an increased level of CTNNB1, including muta-
tions in the CTNNB1 gene and truncated APC [27, 28].
However, to the best of our knowledge, the mechanism by
which CTNNB1 expression is decreased in the cell mem-
brane is still unclear. Few mutations in CTNNB1 and APC
occur in the setting of esophageal cancer [29, 30]. We pre-
viously reported that the accumulation of CTNNB1 in the
nucleus occurs infrequently in esophageal cancer [31].
The CDH1 gene and the CTNNB1 gene are localized
to human chromosomes 16q22.11 [32] and 3p21 [33],
respectively. Many studies have suggested that the
CDH1 locus (16q) and the CTNNB1 locus (3p) may har-
bor tumor suppressor genes for prostate cancer [34] and
bladder cancer [35]. Therefore, the loss of CDH1 may
also contribute to the development of many other types
of cancers. Further studies are required to determine
whether chromosomal losses occurred in the CDH1 and
CTNNB1 loci in the esophageal tumor tissues that were
examined in this study.
We analyzed the expression of CDH1 and CTNNB1
by immunohistochemistry. While our results suggested
that CDH1 or CTNNB1 expression alone did not affect
the prognosis of patients, whether CDH1 and CTNNB1
expression may serve as a good prognostic marker in
esophageal cancer is still controversial. In the meta-
analysis, there are two reports that CDH1 expression
Table 1 Correlation of CDH1 and CTNNB1 expression by IHC
with clinicopathological factors, including patient and tumor
characteristics, in esophageal cancer
No. of patients
(n = 86)
Characteristics Case CDH1(+) p value CTNNB1(+) p value
Age at surgery
<65 years 50 30 18
>65 years 36 15 0.009 13 0.991
Gender
Male 69 40 26
Female 17 5 0.035 5 0.525
Tumor status
T1 17 13 10
T2 8 5 5
T3 37 17 9
T4 24 10 7
T1–2 vs T3–4 0.0088 0.0015
Lymph node status
N0 18 11 10
N1 68 34 21
N0 vs N1 0.40 0.053
Pathological stage
I 13 9 8
II 11 8 5
III 28 15 8
IV 34 13 10
I–II vs III–IV 0.032 0.029
Lymphatic invasion
Negative 16 13 10
Positive 54 26 14
Unknown 16 0.019 0.007
Blood vessel invasion
Negative 30 19 13
Positive 40 20 11
Unknown 16 0.266 0.167
Table 2 Correlation of CDH1 and CTNNB1 expression by IHC
with clinicopathological factors, including patient and tumor
characteristics, in esophageal cancer
No. of patients (n = 86)
Characteristics Case CDH1(+)/CTNNB1(+) p value
Age at surgery
<65 years 50 14
>65 years 36 5 0.119
Gender
Male 69 17

























Ishiguro et al. World Journal of Surgical Oncology  (2016) 14:240 Page 5 of 8alone is a valid prognostic marker [36] and aberrant
CTNNB1 alone is a prognostic factor [37]. Our data sug-
gested that CDH alone or CTNNB1 alone did not affect
the prognosis of the patients with esophageal cancer,
though we could not clarify the discrepancy between
their data and ours.
Some clinical studies have reported that CDH1 ex-
pression is an indicator of poor prognosis or malignant
potential in gastric cancer [38], breast cancer [39], and
non-small cell lung cancer [40].
In this study, we found that the decreased expression
of CDH1 or CTNNB1 in the cell membrane in cancertissues accompanied the local progression and lymph
node metastasis of esophageal cancer (Table 2). In ad-
dition, patients with lower CDH1 or CTNNB1 expres-
sion had a poorer prognosis (Fig. 3). Our data suggested
co-expression of CDH1 and CTNNB1 in the cell mem-
brane might be needed for cell stability because cell in-
stability often causes malignant change of the cancer cell.
In patients with esophageal cancer, many prognostic
markers, including cyclinD1 and mouse double minute 2
homolog (MDM2), have been reported [41, 42]. Further-
more, we have also reported that survivin [43], pituitary
tumor transforming gene 1 (PTTG1) [44], DNA fragmen-










Fig. 3 a Kaplan-Meier survival curve for patients with esophageal cancer whose tumors were classified as either positive or negative for CDH1
and CTNNB1 expression by IHC. Double-positive staining status was found to be strongly associated (log-rank, p = 0.0192) with patient survival
Table 3 Univariate analysis
Parameter Risk ratio 95 % CI p value
Age at surgery
<65 years 1
>65 years 1.573 0.907–2.729 0.107
Gender
Female 1
Male 1.125 0.563–2.247 0.739
Primary tumor
T1–3 1
T4 6.289 3.425–11.49 <0.001
Lymph node metastasis
N0 1
N1 5.812 2.088–16.39 <0.001
Lymphatic invasion
Negative 1
Positive 5.917 1.812–19.23 0.003
Venous invasion
Negative 1
Positive 3.135 1.541–6.369 0.002
Double-positive immunostaining
Negative 1
Positive 2.387 1.115–5.102 0.025
CI confidence interval
Ishiguro et al. World Journal of Surgical Oncology  (2016) 14:240 Page 6 of 8prognostic markers of ESCC. Thus, the decreased ex-
pression of CDH1 or CTNNB1 represents an additional
potential prognostic indicator for patients with ESCC.
Although the precise molecular mechanisms through
which CDH1 or CTNNB1 is downregulated still need to
be clarified, our data clearly indicated that the downreg-
ulation of CDH1 or CTNNB1 may be a prognostic
marker for ESCC. Finally, these proteins may serve as
molecular targets for the development of effective thera-
peutic agents for patients with esophageal cancer.
Conclusions
Decreased expression of CDH1 or CTNNB1 in the cell
membranes of cancer cells is associated with poor
survival of patients with esophageal cancer.
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